 | FRI, MAY 08, 2020 | | | | Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
In the U.S., some states are beginning to reopen businesses despite warnings from the World Health Organization and projections suggesting it will lead to a steady rise in the number of Covid-19 cases and deaths over the next couple of weeks. Meanwhile, supply concerns are emerging for Gilead Sciences' antiviral drug remdesivir after the FDA granted emergency use authorization. More on the outbreak below.
Check out this Q&A with CNBC's Meg Tirrell about the timeline on some of the most promising Covid-19 vaccines and treatments under development right now.
| | Gilead's remdesivir is approved in the US and Japan. Now who's getting the drug? | The first medicine to be approved to treat Covid-19 also happens to be an incredibly complex and time-consuming one to manufacture. Gilead has donated all available supply of remdesivir - about 140,000 to 250,000 treatment courses – to both the U.S. government and entities overseas. But it's not at all clear where the drug is going – either abroad, where it was just approved in Japan, or in the U.S., where the government has taken the unprecedented step of controlling distribution. As advocacy groups call for transparency and equitable access, it's a reminder that the race through clinical development is only half the battle in a pandemic.
-Meg Tirrell | | | | The coronavirus lessons from Asia that the US isn't following | As American states grapple with the complexities of balancing the reopening of businesses with combating the coronavirus pandemic, Asia's successes (and failures) in fighting the virus offers some valuable lessons for the rest of us. From travel restrictions and data sharing to targeted testing and tracing, Asian countries and cities all pursued different strategies. While South Korea and Hong Kong have been hailed for their success, Singapore, Japan and China continue to grapple with resurging outbreaks. Public health specialists and epidemiologists across the region who spoke with CNBC expressed concern that U.S. policymakers haven't learned from Asia. Each of them predicted a long and persistent struggle with Covid-19 in the U.S.
-Will Feuer | | | | Small towns and rural hospitals brace for their coronavirus peak, which could be weeks away | While hospitalizations related to Covid-19 have started to decelerate in some cities, suggesting the worst may be over, it could take the virus weeks to peak in more rural communities across the U.S., health officials warn. Some hospitals haven't had enough medical personnel for decades, are already operating at full capacity or are filling up quickly and don't have enough ventilators to handle a surge of critically ill patients, they say. Dr. Andrew Pavia, pediatric infectious diseases chief at the University of Utah Health, said health disparities between rural and urban communities, where a larger portion of the population are older and have underlying health conditions like obesity and diabetes, could cause a longer, more sustained outbreak in less-densely populated areas rather than a sudden peak, or the increase in the daily rate of new infections as seen in big cities.
-Noah Higgins-Dunn | | | | A more contagious strain is spreading, study says, but some experts are skeptical | A study from researchers at the Los Alamos National Laboratory, led by prominent HIV vaccine researcher Bette Korber, said the coronavirus has mutated at least 14 times since it emerged in Wuhan, China over four months ago. The dominant strain that's now spreading across the United States and other parts of the world appears to be even more contagious. The new strain began spreading in Europe in early February before migrating to other parts of the world, becoming the dominant form of the virus across the globe by the end of March, they said. While some experts said it was plausible, others were skeptical about the study's findings. Additionally, Dr. Francis Collins, director of the National Institutes of Health, said this week the coronavirus doesn't appear to change as quickly as the seasonal flu, meaning scientists won't have to prepare a new vaccine each year.
-Berkeley Lovelace Jr. | | | | Health Insurers are rolling back premiums and co-pays due to Covid | A year ago Bernie Sanders vowed to outlaw health insurers, but right now, the carriers are doing their best to show that they can help providers and consumers stay afloat during this unprecedented health care and financial crisis. There's a sharp drop in spending on medical care now because of widespread cancellations of non-emergency care during the Covid crisis. Now, Humana is giving some cash back to members by waiving co-pays on primary care visits this year, while UnitedHealth Group is committing $1.5 billion for premium rebates and waiving co-pays on all doctor visits for its Medicare Advantage plans through the summer. If trends continue health insurers could pay out record rebates on 2020 plans, under the ACA.
-Bertha Coombs | | Healthy Returns Virtual Summit | May 12, 2020
The path forward for the health care industry at a time of unprecedented challenges
CNBC presents a virtual event featuring top health care CEOs, technologists and investors, exploring the ways the most innovative companies are addressing the coronavirus crisis, and the lasting effects the crisis will have on the industry.
Led by CNBC's anchors and reporters, Healthy Returns will hone in on the groundbreaking ideas that will help mitigate the global pandemic, and will transform the health care industry for years to come. | |
⇉〖OpenLoad〗 2020 Superintelligence Película Completa En Línea released 2020. story: La vida de Carol Peters se trastorna cuando es selecci...
Post a Comment